- Does Preoperative Immunotherapy Improve Treatment of Locally Advanced Rectal Cancer?Immunotherapy May Improve Treatment of Rectal Cancer
- Ipatasertib Precision Cancer Medicine for Prostate CancerAccording to the results of a recent clinical study aggressive prostate cancers may be treated more effectively by combining an existing targeted medicine, Zytiga (abiraterone) with a new experimental drug to block two of cancer’s growth signals at once. The combination delayed prostate cancers ...
- Could Genomic Testing Identify Breast Cancer Patients Who Can Avoid Adjuvant Radiotherapy?POLAR Genomic profile suggest some women with early stage breast cancer might avoid radiation therapy.
- Tislelizumab in Esophageal CancerTislelizumab improved overall survival compared with investigator-chosen standard chemotherapy in patients with esophageal squamous cell carcinoma, according to data from a phase 3 study presented at the ASCO 2021 Annual Meeting. About TislelizumabTislelizumab (BGB-A317) is a type of precision ...
- Elranatamab in Multiple MyelomaWill bispecific antibodies change the treatment of myeloma?
- Mirvetuximab SoravtansineThe Antibody Drug Conjugate Mirvetuximab soravtansine appears promising for treatment of certain patients with ovarian cancer.
- AlrizomadlinCan resistance to immunotherapy be overcome with alrizomadlin?
- Pimitespib Treatment for GISTNovel heat shock protein inhibitor Pimitespib promising for GIST
- Afami-cel Elicits Durable Response Rates in Patients with SarcomaNovel TCR immunotherapy promising for synovial sarcoma
- Rusfertide-a New Option to Avoid Phlebotomy?Can PV patients avoid phlebotomy?
